Intellia Therapeutics's quarterly market cap
declined
from Sep. 2025 ($1,999.64 Mil) to Dec. 2025 ($1,045.69 Mil) but then
increased
from Dec. 2025 ($1,045.69 Mil) to Mar. 2026 ($1,544.14 Mil).
Intellia Therapeutics's annual market cap
declined
from Dec. 2023 ($2,835.48 Mil) to Dec. 2024 ($1,189.67 Mil) and
declined
from Dec. 2024 ($1,189.67 Mil) to Dec. 2025 ($1,045.69 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Intellia Therapeutics's Enterprise Value for Today is $2,032.28 Mil.
Intellia Therapeutics (NAS:NTLA) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Intellia Therapeutics's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Intellia Therapeutics Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Intellia Therapeutics's Market Cap distribution charts can be found below:
* The bar in red indicates where Intellia Therapeutics's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Intellia Therapeutics's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Intellia Therapeutics (NTLA) has a Market Cap of $2,327.77 Mil as of Jun. 28, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Intellia Therapeutics and its competitors. According to the industry distribution chart, Intellia Therapeutics ranks #146 out of 1431 companies in the Biotechnology industry, placing it in the top 10.2%.
Is Intellia Therapeutics' Market Cap too high?
Intellia Therapeutics' current Market Cap is $2,327.77 Mil. The Biotechnology industry median Market Cap is 113.83. Intellia Therapeutics' value of $2,327.77 Mil is 1945% above this industry median. Based on the distribution chart, Intellia Therapeutics ranks #146 out of 1431 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Intellia Therapeutics has a GF Score™ of 70/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Intellia Therapeutics' Market Cap compare to AUPH and OCUL?
According to the Biotechnology industry distribution chart, Intellia Therapeutics ranks #146 out of 1431 companies for Market Cap. This places Intellia Therapeutics in the top 10% of its industry — outperforming the majority of peers. The industry median Market Cap is 113.83. Intellia Therapeutics' value of $2,327.77 Mil is 1945% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 113.83, based on 1,431 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Intellia Therapeutics's current Market Cap of $2,327.77 Mil is 1945% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Intellia Therapeutics and its competitors. For the Biotechnology industry, the median Market Cap is 113.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Intellia Therapeutics's current Market Cap is $2,327.77 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Intellia Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Intellia Therapeutics (NTLA) is currently considered Modestly Undervalued. The stock's GF Value™ is $20.65, compared to a current price of $16.66 — trading 19.3% below its estimated fair value. The current Market Cap is $2,327.77 Mil and 1945% above the Biotechnology industry median of 113.83. Intellia Therapeutics' overall GF Score™ is 70/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Intellia Therapeutics (NTLA), the current Market Cap is $2,327.77 Mil as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Intellia Therapeutics (NTLA) Overvalued in 2026?
Based on GuruFocus' analysis, Intellia Therapeutics stock appears to be undervalued.
The current stock price of $16.66 is trading 19.3% below its estimated GF Value™ of $20.65.
GuruFocus considers Intellia Therapeutics to be Modestly Undervalued.
Key valuation signals for NTLA:
Market Cap: $2,327.77 Mil
GF Value™: $20.65 vs. price of $16.66 (19.3% below fair value)
Industry Position: 1945% above the Biotechnology median (#146 of 1431)
No single metric tells the full story. See the NTLA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
70GF Score
Get the complete analysis for NTLA
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NTLA has been successfully added to your 
